TechCrunch
SEPTEMBER 9, 2021
Neuroglee Therapeutics , a startup developing digital therapeutics for people with neurodegenerative diseases, has raised a $10 million Series A led by Openspace Ventures and EDBI. million to develop digital therapeutics for neurodegenerative diseases. Neuroglee gets $2.3 Venture investing in elder tech.
TechCrunch
APRIL 6, 2022
As a venture firm that invests in psychedelics, we receive hundreds of pitches every month from founders developing psychedelic therapeutics. Our fund has invested more than $15 million in companies developing psychedelic therapeutics. Share on Twitter. Greg Kubin is a partner at PsyMed Ventures and co-host of Business Trip.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch
DECEMBER 3, 2020
Neuroglee , a Singapore-based health tech startup, wants to help with a digital therapeutic platform created to treat patients in the early stages of the disease. one of Japan’s largest pharmaceutical companies, and Kuldeep Singh Rajput, the founder and chief executive officer of predictive healthcare startup Biofourmis.
TechCrunch
JULY 28, 2021
Company co-founder and CEO Brian Harris was a neurologic music fellow at Spaulding Rehabilitation Hospital in Boston, treating people with stroke and brain deficits with music. A year ago, MedRhythms’ digital therapeutic product received Breakthrough Device designation from the U.S. MedRhythms’ product cycle.
TechCrunch
NOVEMBER 3, 2021
BrainCheck , a Houston- and Austin-based company developing cognitive healthcare software to aid physicians in detecting and managing this type of care, raised $10 million in Series B funding to expand its R&D and go-to-market capabilities as it works on new digital therapeutics for Alzheimer’s and related dementias.
Angel Capital Association
MAY 18, 2020
MedRhythms, a Portland, Maine-based digital therapeutics company, is building direct stimulation, prescription therapeutics that use sensors, music, and software to improve loss of mobility caused by neurologic injuries and diseases. How does MedRhythms’ technology work?
TechCrunch
MAY 12, 2023
A recent survey by TechCrunch+ indicates that investors and founders are, instead of simply looking for attractive opportunities, increasingly putting their minds to building the foundations for an industry that can employ the power of psychedelics to change lives.
Expert insights. Personalized for you.
93 
Let's personalize your content